BrightPath Biotherapeutics Overview
- Founded
-
2003
- Status
-
Public
- Employees
-
44
- Stock Symbol
-
4594
- Share Price
-
$1.34
- (As of Wednesday Closing)
BrightPath Biotherapeutics General Information
Description
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
Contact Information
Website
www.brightpathbio.com
Formerly Known As
GreenPeptide Co., Ltd., GreenPeptide
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
TKS
Primary Office
- Fukuoka Bio Incubation Center, 1-1 Hyakunenkoen
- Kurume-shi
- Fukuoka, 839-0864
- Japan
+81 0000-00-0000
BrightPath Biotherapeutics Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.34 | $1.32 | $0.41 - $1.84 | $84.1M | 62.9M | 7.2M | -$0.22 |
BrightPath Biotherapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | 31,380 | 23,499 | 54,267 | 51,491 |
| Revenue | 155 | 137 | 24 | 104 |
| EBITDA | (12,874) | (15,566) | (16,531) | |
| Net Income | (12,410) | (13,211) | (16,217) | (17,086) |
| Total Assets | 15,062 | 22,706 | 33,988 | 32,151 |
| Total Debt | 0 | 717 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
BrightPath Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BrightPath Biotherapeutics Patents
BrightPath Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4140501-A1 | Improved peptide vaccine | Pending | 23-Apr-2020 | 000000000 | |
| EP-4006148-A1 | Method for producing cell population containing car-expressing immune cells | Pending | 31-Jul-2019 | 000000000 | |
| US-20220265714-A1 | Method for producing cell population containing car-expressing immune cells | Pending | 31-Jul-2019 | 000000000 | |
| US-20220313803-A1 | Novel neoantigens and cancer immunotherapy using same | Pending | 07-Jan-2019 | 000000000 | |
| JP-6142384-B1 | Reagent for antibody test | Active | 14-Sep-2016 | G01N33/53 |
BrightPath Biotherapeutics Executive Team (7)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Kenichi Nagai | President & Chief Executive Officer | ||
| Teruhiko Sakai | Chief Financial Officer & Director | ||
| Yutaka Waki | Chief Operating Officer | ||
| Kyogo Ito | Founding Scientist |
BrightPath Biotherapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
BrightPath Biotherapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
